Casirivimab and imdevimab: cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with covid-19

HIGHLIGHTS

• who: Matteo Ruggeri and collaborators from the Istituto Superiore di Sanitu00e0 (ISS), Italy, StCamillus International University of Health Sciences have published the research: Casirivimab and imdevimab: Cost-effectiveness analysis of the treatment based on monoclonal antibodies on outpatients with Covid-19, in the Journal: PLOS ONE of June/27,/2022
• what: This analysis determines the variation of one or more parameters on the results of the model by focusing on the parameters most sensitive to the onset of a variation. This study shows the benefits that the use of cas and amp;im treatment can . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.